Register for free to
view the full innovation profile.
The ease of administration makes this useful for large-scale field administration, for use with pediatric or elderly patients as well as patients in Third-World populations.
About
Summary This invention is a method of vaccinating against human papillomavirus (HPV) by using papillomavirus ?virus-like particles? transcutaneously to induce an immune response to the virus. Papiloma viruses constitute a group of DNA viruses that induce both lytic infections and either benign or malignant tumors. Papiloma viruses infect cutaneous, genital, oral, and respiratory epithelia in a tissue-specific manner. Infection with HPV has been associated closely with plantar warts, condylomata acuminata (anogenital warts), and premalignant and malignant lesions of the cervical squamous epithelium.